Adenylyl cyclaseassociated protein 1targeted nanoparticles as a novel strategy for the treatment of metastatic nonsmall cell lung cancer.
Int J Oncol
; 55(2): 462-472, 2019 Aug.
Article
em En
| MEDLINE
| ID: mdl-31173184
ABSTRACT
Nonsmall cell lung cancer (NSCLC) is one of the most fatal cancers worldwide. Adenylyl cyclaseassociated protein 1 (CAP1) belongs to a family of cyclaseassociated proteins that are involved in the development of cancerous tumors. A previous study by our group confirmed the association between CAP1, lung cancer and the metastasis of cancer cells. In the present study, poly(lacticpolyglycolic acid; PLGA)/CAP1small interfering (si)RNA nanoparticles were prepared and delivered into A549 cells. The performance of PLGA/siCAP1siRNA nanoparticles for siRNA delivery was measured based on the results of migration assay and animal experiments. The multifunctional nanoparticles were determined to be capable of inhibiting CAP1 expression, which reduced NSCLC metastasis in vitro and in vivo. Therefore, the findings of the current study highlighted the potential use of PLGA/siCAP1siRNA nanoparticles for the treatment of NSCLC metastasis.
Texto completo:
1
Base de dados:
MEDLINE
Assunto principal:
Carcinoma Pulmonar de Células não Pequenas
/
Proteínas de Ciclo Celular
/
Proteínas do Citoesqueleto
/
RNA Interferente Pequeno
/
Nanopartículas
/
Neoplasias Pulmonares
Idioma:
En
Ano de publicação:
2019
Tipo de documento:
Article